VENUSS prognostic model for papillary kidney cancer

A recent study published in BMC Medicine this month investigates clinical and pathological variables and outcomes of 556 patients with papillary renal cell carcinoma (RCC) with the view to developing a scoring system to help predict the likely course of the disease in patients (a prognostic scoring system). The VENUSS prognostic score included the presence […]

read more

ESMO 2018: Adjuvant axitinib versus placebo in patients at high risk of RCC recurrance

Results from the latest adjuvant study with a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI), axitinib (Inlyta), were presented at the European Society of Medical Oncology (ESMO) 2018 conference in Munich over the weekend. Results of clinical trials assessing adjuvant therapy for intermediate- and high-risk renal cell carcinoma (RCC) with VEGF TKIs have […]

read more

A test to gauge recurrence risk for kidney cancer is unable to predict which patients will benefit from adjuvant therapy

An American company called Genomic Health has been collaborating with Pfizer over the past 10 years to develop a 16-gene expression test to determine the chances of recurrence of kidney cancer after surgery. The test was validated in a study, which was published in The Lancet Oncology in 2015. The validation study showed that the […]

read more

16-gene recurrence score for high-risk kidney cancer offers prognostic value

Results from a phase III trial presented at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting held in Chicago last week confirmed the prognostic value of a 16-gene recurrence score (RS) in patients with high-risk renal cell carcinoma (RCC) undergoing adjuvant sunitinib therapy. Though the score cannot yet be used to select patients […]

read more
Showing all 4 results